Compared to vehicle controls, increases in Col1a1 area were less pronounced in AMLN ob/ob-NASH mice receiving OCA 30 mg/kg (10.5 ± 0.4%, p < 0.01), ELA 3 mg/kg (9.7 ± 0.8%, p < 0.001), or ELA 10 mg/kg (8.9 ± 0.6%, p < 0.001) treatment. Here, COL1A1 is linked to metabolic dysfunction-associated steatohepatitis.